Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Rating of “Hold” from Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $16.00.

A number of analysts have recently issued reports on OFIX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a report on Friday, July 17th. Barrington Research lifted their target price on Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Wall Street Zen cut shares of Orthofix Medical from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. TD Cowen reaffirmed a “hold” rating on shares of Orthofix Medical in a report on Thursday, May 21st. Finally, Stifel Nicolaus reduced their price target on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd.

Insider Transactions at Orthofix Medical

In related news, insider Aviva Mcpherron sold 3,670 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.38, for a total value of $34,424.60. Following the sale, the insider owned 66,330 shares of the company’s stock, valued at $622,175.40. This trade represents a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John B. Henneman III purchased 5,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was purchased at an average price of $12.26 per share, for a total transaction of $61,300.00. Following the purchase, the director directly owned 90,809 shares of the company’s stock, valued at $1,113,318.34. This trade represents a 5.83% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 76,946 shares of company stock worth $939,700. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Orthofix Medical

Large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in shares of Orthofix Medical in the fourth quarter worth about $56,000. CWM LLC lifted its stake in Orthofix Medical by 136.4% in the fourth quarter. CWM LLC now owns 4,538 shares of the medical device company’s stock valued at $69,000 after acquiring an additional 2,618 shares during the last quarter. Abel Hall LLC bought a new stake in Orthofix Medical in the first quarter worth $139,000. Mackenzie Financial Corp acquired a new position in shares of Orthofix Medical during the 3rd quarter valued at about $148,000. Finally, Strs Ohio acquired a new position in Orthofix Medical during the first quarter valued at approximately $150,000. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Price Performance

Shares of NASDAQ:OFIX opened at $12.26 on Tuesday. The stock has a market cap of $495.55 million, a PE ratio of -8.12 and a beta of 0.68. The business’s fifty day moving average price is $10.41 and its two-hundred day moving average price is $11.79. Orthofix Medical has a one year low of $8.85 and a one year high of $16.99. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.76 and a current ratio of 2.87.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings results on Tuesday, May 5th. The medical device company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.16. The business had revenue of $196.71 million during the quarter, compared to the consensus estimate of $196.40 million. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. On average, analysts forecast that Orthofix Medical will post -1.4 EPS for the current fiscal year.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.